Finasteride is not a peptide. It is included because it is, alongside minoxidil, one of the two pillars of pharmacologic hair loss treatment, and because the conversation around its adverse effects is one clinicians must be able to handle without either dismissing patients or alarming them.
This guide situates Finasteride within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
Why DHT drives androgenetic alopecia
In androgenetic alopecia, genetically susceptible follicles undergo progressive miniaturization: with each cycle the anagen phase shortens and the follicle produces a finer, shorter hair, until it yields only vellus hair or none.
The driver is dihydrotestosterone (DHT), a more potent androgen converted from testosterone by the enzyme 5-alpha-reductase. Susceptible follicles carry androgen receptors that respond to DHT by miniaturizing.
The genetic contribution determines which follicles are susceptible, which is why the pattern is characteristic — and why occipital follicles resist the process and can be transplanted successfully.
Finasteride inhibits type II 5-alpha-reductase, the isoenzyme predominant in hair follicles and prostate, substantially lowering serum and scalp DHT while leaving testosterone largely intact. Dutasteride inhibits both type I and type II and lowers DHT further; it is approved for BPH and used off-label for hair.
What finasteride achieves
The evidence for finasteride at 1 mg in male pattern hair loss is substantial and consistent, from large randomized placebo-controlled trials with multi-year follow-up. It is among the better-evidenced interventions in aesthetic medicine.
The realistic outcome should be framed accurately. The dominant benefit is halting progression. Most treated men maintain or improve hair count while placebo groups continue to lose. A meaningful proportion see visible regrowth, generally modest, most often at the vertex.
That framing matters for satisfaction. A patient expecting restoration of a childhood hairline will be disappointed by a drug that is performing exactly as evidenced. A patient who understands that the goal is keeping what they have, with some regrowth possible, is far better served.
As with minoxidil, the effect is dependent on continued use. Discontinuation returns the patient to their natural trajectory within about a year.
The persistent side effect question
This requires a careful and honest treatment, because both dismissal and alarm fail patients.
What trials show: sexual adverse effects — reduced libido, erectile dysfunction, ejaculatory disorder — occur in a small percentage of men, with rates in randomized trials low and often not far above placebo, and typically resolving on discontinuation or even during continued use.
What is contested: a body of reports describes sexual dysfunction, and in some accounts cognitive and mood symptoms, that persist after stopping the drug — sometimes termed post-finasteride syndrome. This has generated substantial patient advocacy, regulatory attention and label changes in several jurisdictions, including warnings regarding persistent sexual dysfunction and, in some regions, depression and suicidal ideation.
Where the science actually sits: whether a distinct persistent syndrome exists, its frequency, and its mechanism remain genuinely unresolved. Observational data are confounded by the nocebo effect, which is well documented with this drug, by the fact that sexual dysfunction is common in the general population, and by ascertainment bias in self-reported registries. Equally, absence of confirmation is not proof of absence, and the reports are numerous enough that flat dismissal is not defensible.
What this means practically: the honest consent conversation states that the drug is effective and well evidenced, that side effects in trials are uncommon and usually reversible, that a contested question exists about persistent effects which the evidence has not settled, and that discontinuation is always available. Men should also be counselled to report new mood symptoms. A patient given that information can make a genuine decision; a patient told either that the concern is nonsense or that the drug is dangerous cannot.
Practical considerations
Finasteride reduces serum PSA by roughly half in men taking it, which must be accounted for in prostate cancer screening — a PSA result should be interpreted with the medication known, and doubling is the conventional adjustment. Failing to flag this can delay a cancer diagnosis.
It is contraindicated in women who are or may become pregnant, because inhibiting DHT can affect development of male external genitalia. Broken or crushed tablets should not be handled by pregnant women; coated tablets are safe to handle intact.
Finasteride is used off-label in women in some settings, but not in those of childbearing potential without reliable contraception and specialist involvement.
In combination with minoxidil, which works by an unrelated mechanism, outcomes are better than with either alone — the standard approach for men pursuing medical management of androgenetic alopecia.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering androgen biology and hair loss treatment, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →